Brief: PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients
09/11/2023 13:12
Nov 9 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECH ANNOUNCES UPDATED SURVIVAL DATA FROM NCI-LED
PHASE 2
CLINICAL TRIAL OF PDS0101-BASED TRIPLE COMBINATION THERAPY IN
ADVANCED HPV16-POSITIVE CANCER PATIENTS WHICH SHOW 75% SURVIVAL
OF ICI NAÏVE PATIENTS AT 36 MONTHS
* PDS BIOTECHNOLOGY CORP: 12-MONTH SURVIVAL RATE IN ICI
RESISTANT
PATIENTS IS 72% IN STUDY
* PDS BIOTECHNOLOGY CORP: MEDIAN OS IN ICI RESISTANT
PATIENTS IS
APPROXIMATELY 20 MONTHS; PUBLISHED MEDIAN OS IS 3.4 MONTHS IN
STUDY
Source text for Eikon: ID:nGNX7d5Xlt
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing